SCHEMBL4772238

SCHEMBL4772238

CCOC(=O)C1C=CC=CN1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
GLA P06280 2/20 0.37
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
NR1H2 P55055 1/20 0.33
CTSL P07711 1/20 0.33
KDM4E B2RXH2 2/20 0.32
HTT P42858 2/20 0.32
HPGD P15428 1/20 0.32
RECQL P46063 1/20 0.32
HSD17B10 Q99714 1/20 0.32
GAA P10253 1/20 0.32
PKM P14618 1/20 0.32
CTSK P43235 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28842147 0.86 NR1H2 (0.34) KMT2AMEN1ALDH1A1MAPTNR1H2
SCHEMBL27721708 0.83 PDE4B (0.36) KMT2AALDH1A1NR1H2HPGD
SCHEMBL28556370 0.82 NR1H2 (0.33) NR1H2
SCHEMBL28102330 0.76 LMNA (0.36) KMT2AMEN1GLANFKB1NFKB2
SCHEMBL28428311 0.73 CHRM2 (0.39) KMT2AMEN1MAPTNR1H2KDM4E
SCHEMBL28107442 0.73 USP2 (0.37) KMT2AMEN1NR1H2KDM4EHPGD
SCHEMBL1163661 0.72 GLA (0.41) KMT2AMEN1ALDH1A1TSHRGLA
SCHEMBL1571674 0.72 GLA (0.41) KMT2AMEN1ALDH1A1TSHRGLA
SCHEMBL13519523 0.72 NFKB1 (0.41) KMT2AMEN1ALDH1A1TSHRGLA
SCHEMBL6789639 0.72 NFKB1 (0.41) KMT2AMEN1ALDH1A1TSHRGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111225915-B Imidazopyridine compounds as PAD inhibitors 朱比兰特埃皮帕德有限公司 2023-03-07 CN disclosed
CN-115038688-A USP30 inhibitors and uses thereof 文森雷生物科学股份有限公司 2022-09-09 CN disclosed
CN-111225915-A Imidazopyridine compounds as PAD inhibitors 朱比兰特埃皮帕德有限公司 2020-06-02 CN disclosed
CN-104540825-B Azaindole quinoline compound 霍夫曼-拉罗奇有限公司 2017-10-24 CN disclosed
EP-1966199-A1 AZAINDOLE-2-CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
WO-2007057329-A1 AZAINDOLE-2-CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-05-24 WO disclosed
US-7208494-B2 5HT2c receptor agonists HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
EP-1641796-A1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY F. HOFFMANN-LA ROCHE AG (CH) 2006-04-05 EP disclosed
US-20050026925-A1 5HT2c receptor agonists HOFFMANN-LA ROCHE INC. 2005-02-03 US disclosed
WO-2005000849-A1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY F. HOFFMANN-LA ROCHE AG (CH) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026925-A1 5HT2c receptor agonists HTR2C, HTR2A, HTR5A KMT2A 1087/4885MEN1 2635/4885ALDH1A1 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.